Connect with us

News

The Future of femtech: Rebuilding the investment landscape

Published

on

By Melissa Wallace, co-founder, Fierce Foundry

For decades, women’s health was treated as an afterthought, underfunded, under-researched, and often dismissed as “niche.”

Yet the irony is staggering: women make up 51 per cent of the population and drive nearly 80 per cent of consumer purchasing decisions.

The gap is rarely about market potential, because we know it is huge! It comes down to who holds the capital, who sets the governance, and whose lived experiences shape investment decisions.

Many of us see this as an opportunity, and now a growing wave of organisations are working to rebuild the investment landscape with women at the centre. Fierce Foundry, How Women Invest, The Fourth Effect, Female Founders Fund, All Raise, and countless grassroots angel networks are proving that women at the table means change.

The organisations are creating new pathways for women to become investors, supporting founders with more transparent funding relationships, and shifting the narrative on what it means to scale a business.

THIS is what is laying the foundation for the next generation of femtech innovation.

More Women Investors Changes Everything

People invest in what they understand and relate to.

When a woman develops a breakthrough medical device for PCOS patients, a male investor may not immediately recognise its value, even if the numbers are strong.

That’s not about blame, it’s about perspective.

When women step into investment roles, the impact is measurable:

Backing overlooked markets.

Female investors have been early champions of companies once ignored by traditional VCs.

Female Founders Fund backed Maven Clinic when “women’s health” wasn’t on Sand Hill Road’s radar.

Elvie, a pioneer in connected breast pumps and pelvic floor trainers, scaled globally because women investors recognised the scale of the problem and the purchasing power of women.

Without women at the table, these companies may have never broken through.

Bringing a wider lens of critical thinking.

Women tend to evaluate opportunities across multiple dimensions: returns, customer well-being, and long-term sustainability.

This broader perspective surfaces both risks and opportunities that can otherwise be missed. It’s not “soft” thinking; it’s smart investing.

                     Melissa Wallace

Delivering results through leadership.

Data shows that women-led companies outperform their leadership counterparts.

A BCG study found startups founded and co-founded by women generate 10 per cent  more cumulative revenue over a five-year period, despite raising less capital.

Women investors see that performance potential early and help accelerate it.

This isn’t about charity. It’s about smarter bets and the numbers back it up.

The Blueprint for Change

The question isn’t whether FemTech will thrive. It’s what needs to shift for it to thrive faster. From my perspective, three things are critical:

  1. Pathways for Women to Become Investors. We need more women with capital, and that means more exits for women founders, broader education on accredited investing, and new models that democratise access to wealth.
  2. A Redesign of Venture Structures. Traditional VC models were never built with women in mind. They reward hypergrowth at any cost, punish flexibility, and replicate outdated power dynamics. At Fierce Foundry, we’re experimenting with venture studio models that align with how women actually lead; embedding shared services, designing with empathy, and even considering how work cycles could align with women’s hormonal cycles for exceptional performance.
  3. A Culture of Networks, Not Gatekeepers. Fundraising is rarely about one pitch; it’s about the introductions that compound over time. By building “networks of networks,” grounded in transparency and reciprocity, we ensure women founders gain access to capital where it has historically been blocked.

Lessons From the Frontlines

For FemTech founders, the challenge isn’t just finding any investor, it’s finding the right investor.

The wrong money can derail a company just as quickly as no money.

The most successful women founders I know focus on three things:

  1. Invest in aligned capital. Before taking money, research who your investors are, what they’ve funded, and how they show up for founders. The best partnerships are 10-year marriages, you need conviction on both sides.
  2. Build with transparency. Women founders are often asked tougher questions, but the best defense is clarity. Own your numbers, your risks, and your strategy. The right investors will respect honesty over spin.
  3. Leverage networks strategically. Don’t just network for introductions, network for champions. Each “no” can lead to two or three more conversations if you leave the door open. The founders who excel are the ones who convert networks into ecosystems of support.

At Fierce Foundry, I’ve seen this firsthand.

The women we work with not only find capital, but they also attract investors who believe in them as much as in the product.

That’s when the flywheel starts: funded women lead to exits, which lead to new women investors, which fuels the next generation of founders.

A Future Worth Building

If the investment landscape reached true gender balance, FemTech wouldn’t be a “category”, instead, it would simply be part of the mainstream.

We would see more women founders funded, more exits leading to more women investors, and workplaces redesigned to reflect how people actually thrive.

That future is not hypothetical.

I see glimpses of it every day at Fierce Foundry, where women are co-building companies with us from idea to exit.

The more we expand pathways for women investors, reimagine venture models, and build networks of networks, the faster we get there.

The next decade could be the tipping point for FemTech if we choose to rebuild the system with women at its core.

And when we do, the industry won’t just thrive. It will redefine what innovation looks like for everyone.

Insight

Early PET scan could chemo response in aggressive breast cancer – study

Published

on

An early PET scan after one cycle of chemotherapy may help predict how aggressive breast cancer responds to treatment, a study suggests.

Research led by The Institute of Cancer Research, London and King’s College London suggests that an early scan taken after one cycle of chemotherapy could help predict how well a patient’s cancer will respond to treatment.

The study focused on patients with triple-negative breast cancer (TNBC), an aggressive form of the disease in which cancer cells lack receptors for the hormones oestrogen and progesterone, as well as the HER2 protein.

Patients with TNBC are usually treated with chemotherapy prior to surgery. While many respond well, residual disease at surgery, typically around six months later, is associated with a significantly poorer prognosis. Identifying people sooner who are unlikely to respond remains a major clinical challenge.

The research explored whether using PET imaging shortly after treatment begins, rather than relying only on MRI scans later in the treatment process, could provide earlier insight into how a patient’s cancer is responding. Twenty-two patients were recruited, with fourteen undergoing FDG-PET scans before treatment and after the first cycle of chemotherapy.

The findings, published in Clinical Cancer Research, showed that changes seen on PET scans after just one cycle of chemotherapy were strongly associated with subsequent response, including whether there was no detectable cancer, known as a complete response, by the end of treatment. Importantly, early PET response showed stronger associations with treatment outcomes than standard mid-treatment MRI scans in this study.

Being able to identify patients who are not responding well at an early stage could allow clinicians to adjust treatment sooner or consider alternative approaches. These findings may also support future strategies to better tailor treatment intensity to individual patients.

The study also compared two types of PET tracers, FDG and FLT, to determine which was most suitable. While both met the study’s technical criteria, FDG-PET was selected for further evaluation due to its better image quality, greater consistency and wider use in clinical practice.

The research also explored how imaging changes after just one cycle of chemotherapy relate to the body’s immune response to treatment. Biopsies taken before and after the first cycle of chemotherapy showed that an increase in immune cells within the tumour was strongly associated with both early PET changes and improved treatment outcomes.

The researchers emphasise that these findings now need to be validated in larger studies. Future work will aim to confirm these results in broader patient groups and explore more accessible imaging approaches, such as ultrasound, alongside PET and MRI.

Sheeba Irshad, professor of cancer immunology at King’s College London and lead of the Breast Cancer Now KCL Research Unit, said:

“In patients who had PET scans both before treatment and after the first cycle, we found that this early scan could predict whether they were likely to achieve a complete response by the end of treatment. These findings highlight the potential of early imaging to guide treatment decisions, and now need to be validated in larger, modern clinical trials.”

Andrew Tutt, professor of breast oncology at The Institute of Cancer Research, London, said:

“Research that helps us determine early who is already benefitting from standard neoadjuvant chemotherapy and who might benefit from clinical trials to find better treatments is vital. This study shows that FDG-PET may have great value in this regard. We hope to be able to design studies that further investigate and validate these findings.”

The study was supported by funding from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, Breast Cancer Now, Cancer Research UK, and Guy’s and St Thomas’ Charity.

Continue Reading

News

Femtech World reveals startup of the year shortlist

Published

on

We are excited unveil the three finalists competing for one of the Femtech World Awards’ most coveted honours: the Startup of the Year Award, sponsored by Future Fertility.

This award celebrates an early-stage company making a bold impact in women’s health through innovation, vision and execution.

The winner will be announced at our virtual ceremony on 19 June, with the decision made by a representative from category sponsor Future Fertility.

Congratulations to the shortlist and thank you to everyone who entered or nominated.

Startup of the Year Shortlist

Hello Inside is the first women’s health AI company to turn daily metabolic signals into outcomes women feel and healthcare systems reimburse.

Women’s health has long been under-researched, and current AI benchmarks fail on women’s health questions roughly sixty percent of the time.

Hello Inside built the architecture to close that gap.

Across four years and 12,000+ validated metabolic profiles, three in four women improve at least one symptom within ninety days.

They lose four kilograms in three months, moving from overweight into the healthy range. In a clinical study with Alisa Vitti’s Flo Living, 91.9 per cent reduced PMS burden within sixty days.

OvartiX is doing something that has never been done before: building a drug discovery engine purpose-built for women’s health.
Its lead programme, OVX001, targets medically induced menopause – a condition affecting young female cancer patients who undergo chemotherapy or radiotherapy.
These women are cured of cancer but enter menopause overnight.
There is currently no approved drug to prevent it. OVX001 is designed to change that, preserving 80–95 per cent of ovarian follicles during treatment without compromising anti-tumour efficacy.
Behind the science is the OmiXX platform: the first ML-driven drug discovery tool built specifically for female physiology, using proprietary ovarian cellular models and human multi-omics data.

U-Ploid is an early-stage biotechnology company tackling one of the most fundamental challenges in fertility care: the sharp, age-related decline in egg quality that limits outcomes across IVF and egg freezing.

While much of the field focuses on improving assessment and selection, U-Ploid is developing a first-in-class therapeutic approach designed to improve egg quality itself by addressing the biological causes of age-related chromosomal errors.

Supported by strong preclinical evidence and now advancing into human studies, U-Ploid combines scientific rigour, regulatory discipline and long-term vision to help redefine what is possible in fertility care.

Continue Reading

News

Gestational diabetes increases risk of type 2 diabetes – even at normal weight, study finds

Published

on

Gestational diabetes is a strong risk factor for future type 2 diabetes, even in women with normal pre-pregnancy weight, according to a study at the University of Gothenburg.

The researchers call for earlier testing and better follow-up.

“Our results show that gestational diabetes functions as a kind of stress test for the body’s ability to manage blood sugar, and identifies women with a greatly increased risk of future type 2 diabetes”, said Jon Edqvist, PhD and affiliated to research at the University of Gothenburg, and operating room nurse at Sahlgrenska University Hospital.

Gestational diabetes is a special type of diabetes that can affect pregnant women.

The condition is defined as elevated blood sugar levels, without previously known diabetes. Treatment involves self-monitoring of blood sugar, advice on lifestyle habits and, if necessary, medication.

Identifying gestational diabetes is important because the disease increases the risk of complications such as preeclampsia, the need for a cesarean section and high birth weight for the baby.

Those who have had gestational diabetes are also at higher risk of later developing type 2 diabetes.

In the current study, published in eClinicalMedicine, researchers now show that gestational diabetes is a strong indicator of future risk of developing type 2 diabetes, even in women with normal weight before pregnancy.

Elevated risk even with normal weight

The study is based on data from the Medical Birth Registry on just over 1.15 million first-time mothers in Sweden, who gave birth between 1987 and 2019. 16,870 women with confirmed gestational diabetes were compared with age-matched women without the diagnosis. The median follow-up period was nine years.

The results show that women with a BMI of 35 and above, i.e. severe obesity, had an almost tenfold increased risk of developing gestational diabetes compared to women with normal weight.

The risk of subsequent type 2 diabetes also increased with higher BMI, but it was significantly increased even with normal weight, which the researchers describe as particularly worrying.

More follow-up and more studies

The researchers behind the study welcome the recently updated recommendations on gestational diabetes in Sweden, where a higher proportion of pregnant women at increased risk are expected to be offered testing earlier in pregnancy, and if necessary, interventions.

“Diagnostics and care of gestational diabetes have looked very different in different parts of the country,” said Annika Rosengren, professor at the University of Gothenburg.

“There is a need for both improved follow-up after gestational diabetes, and more studies that investigate how such follow-up affects future health and prognosis”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.